Challenges in the Control and Eradication of Malaria

  • Ignatius W. FongEmail author
Part of the Emerging Infectious Diseases of the 21st Century book series (EIDC)


Malaria is still the most important parasitic disease in the world, and tropical developing countries or resource-poor areas face daunting challenges to control and eradicate this pervasive infection. Although progress has been made over the past century in shrinking the malaria map, more than 40 % of the world’s population are at risk of contracting malaria [1]. Most recent estimates on the annual burden of malaria worldwide are several hundred million cases with about 800,000 deaths per year [1]. Snow et al. [2] estimated that there were 515 million cases of clinical malaria caused by Plasmodium falciparum alone in 2002. However, in the past 150 years, about half of the countries in the world eliminated malaria [3]. Presently, there are 99 countries with endemic malaria, of which 67 are controlling malaria to a large degree and 32 are in the process of trying to eliminate this parasite [3].


Malaria Transmission Malaria Control Antimalarial Drug Severe Malaria Insecticide Resistance 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Kappe SH, Vaughan AM, Boddey JA, Cowman AF (2010) This was then but this is now: malaria research in the time of an eradication agenda. Science 328:862–866PubMedGoogle Scholar
  2. 2.
    Snow RW, Guerra CA, Noor AM, Mywit HY, Hay ST (2005) The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature 434:214–217PubMedGoogle Scholar
  3. 3.
    Feachem RG, Philips AA, Hwang J et al (2010) Shrinking the malaria map: progress and prospects. Lancet 376:566–578Google Scholar
  4. 4.
    Schreiber W, Mathys FK (1987) Malaria. In: Infectio. Infectious Diseases in the history of medicine. Hoffman La Roche & Co. Ltd, Basle, pp 213–223Google Scholar
  5. 5.
    Zucker JR (1996) Changing patterns of autochthonous malaria transmission in the United States: a review of recent outbreaks. Emerg Infect Dis 2:37–43PubMedGoogle Scholar
  6. 6.
    Rich S, Ayala FJ (2006) Evolutionary origins of human malaria parasites. In: Dronamraju KR, Arese P (eds) Malaria: Genetic and evolutionary aspects. Springer, New York, pp 125–146Google Scholar
  7. 7.
    Sherman IW (ed) (1998) A brief history of malaria and the discovery of the parasites life cycle. In: Malaria: parasite biology, pathogenesis and protection. American Society of Microbiology, Washington, DC, pp 3–10Google Scholar
  8. 8.
    Miller RL, Ikram S, Armelagos GI et al (1994) Diagnosis of Plasmodium falciparum infections in mummies using the rapid manual ParasightTM – F test. Trans R Soc Trop Med Hyg 88:31–32PubMedGoogle Scholar
  9. 9.
    Cox-Singh J, Davis TM, Lee KS et al (2008) Plasmodium knowlesi malaria in humans is widely distributed and potentially life threatening. Clin Infect Dis 46:165–171PubMedGoogle Scholar
  10. 10.
    Putaporntip C, Hongsrimuang T, Seethamchai S, Kobasa T, Limkittikul K, Cui L, Jongwatiwes S (2009) Differential prevalence of Plasmodium infections and cryptic Plasmodium knowlesi malaria in humans. J Infect Dis 199:1143–1150PubMedGoogle Scholar
  11. 11.
    Price RN, Tjitra E, Guerra CA, Yeung S, White NJ, Anstey NM (2007) Vivax Malaria: Neglected and not benign. Am J Trop Med Hyg 77(6 suppl):79–87PubMedGoogle Scholar
  12. 12.
    Hay SI, Guerra CA, Tatem AJ, Noor AM, Snow RW (2004) The global distribution and population at risk of malaria; past, present and future. Lancet Infect Dis 4:327–336PubMedGoogle Scholar
  13. 13.
    WHO (1999) Making a difference. The world health report 1999. Health Millions 25:3–5Google Scholar
  14. 14.
    Brito I (2001) Eradicating Malaria: high hopes or a tangible goal? Health Policy Harv 2:61–66Google Scholar
  15. 15.
    Roberts DR, Manguin S, Moucher J (2000) DDT house spraying and re-emerging malaria. Lancet Infect Dis 356:330–332Google Scholar
  16. 16.
    Greenwood BM, Fidock DA, Kyle DE, Kappe SH, Alonso PL, Collings FH, Duffy PE (2008) Malaria: progress, perils and prospects for eradication. J Clin Invest 118:1266–1276PubMedGoogle Scholar
  17. 17.
    Wellems TE, Plowe CV (2001) Chloroquine resistant malaria. J Infect Dis 184:770–776PubMedGoogle Scholar
  18. 18.
    Trape JF, Pison G, Preziozi MP et al (1998) Impact of chloroquine resistance on malaria mortality. C R Acad Sci III 32:689–697Google Scholar
  19. 19.
    WHO (2004) The Abija declaration and the plan of action. An extract from the African Summit on Roll Back Malaria, Abija, 25 Apr 2000 (WHO/CDS/RBM/2000.17).
  20. 20.
    Sachs JD, McArthur JW (2005) The Millennium Project: a plan for meeting the Millennium Goals. Lancet 365:347–353PubMedGoogle Scholar
  21. 21.
    Global Fund to Fight AIDS, Tuberculosis and Malaria (2009) Commitments and disbursements.
  22. 22.
    Snow RW, March K (2010) Malaria in Africa: progress and prospects in the decade since the Abrija declaration. Lancet 376:137–139PubMedGoogle Scholar
  23. 23.
    Ceesay SJ, Casals-Pascual C, Erskine J et al (2008) Changes in Malaria indices between 1999 and 2007 in The Gambia: a retrospective analysis. Lancet 372:1545–1554PubMedGoogle Scholar
  24. 24.
    Kleinschmidt I, Schwadbe C, Benavente L et al (2009) Marked increase in child survival after four years of intensive malaria control. Am J Trop Med Hyg 80:882–888PubMedGoogle Scholar
  25. 25.
    O’Meara WP, Bejoin P, Mwangi TW et al (2008) Effect of a fall in Malaria transmission on morbidity and mortality in Kilifi, Kenya. Lancet 372:1555–1562PubMedGoogle Scholar
  26. 26.
    Enserink M (2010) Redrawing Africa’s Malaria map (news). Science 328:842PubMedGoogle Scholar
  27. 27.
    Dundorp AM, Nosten F, Yi P et al (2009) Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 361:455–467Google Scholar
  28. 28.
    Mehlotra RK, Zimmerman PA (2006) Resistance to antimalarials drugs: parasite and host genetic factors. In: Dronamraju KR, Arese P (eds) Malaria: genetic and evolutionary aspects. Springer, New York, pp 81–124Google Scholar
  29. 29.
    Yeung S, Van Damme W, Socheat D, White NJ, Mills A (2008) Access to artemisinin combination therapy for malaria in remote areas of Cambodia. Malar J 7:96PubMedGoogle Scholar
  30. 30.
    Roper C, Pearce R, Nair S, Sharp B, Nosten F, Anderson T (2004) Intercontinental spread of pyrimethamine-resistant malaria. Science 305:1124PubMedGoogle Scholar
  31. 31.
    Verdragger J (1986) Epidemiology of the emergence and spread of drug-resistant falciparum malaria in South East Asia and Australasia. J Trop Med Hyg 89:277–289Google Scholar
  32. 32.
    Cortese JF, Caraballo A, Contreras CE (2002) Origin and dissemination of Plasmodium falciparum drug mutations in South America. J Infect Dis 186:999–1006PubMedGoogle Scholar
  33. 33.
    Pickard AL, Wongsrichanalai C, Pinfied A et al (2003) Resistance to antimalarials in Southeast Asia and genetic polymorphisms in pfmdrl. Antimicob Agents Chemother 47:2418–2423Google Scholar
  34. 34.
    Cerutti CJR, Dunlacher RP, de Alencar FE et al (1999) In vivo efficacy of mefloquine for treatment of falciparum malaria in Brazil J. Infect Dis 180:2077–2080Google Scholar
  35. 35.
    Wichman O, Betschart B, Loscher T et al (2003) Prophylaxis failure due to probably mefloquine resistant P. falciparum from Tanzania. Acta Trop 86:63–65Google Scholar
  36. 36.
    Guerin PJ, Olliaro P, Nosten F et al (2002) Malaria: current status of control, diagnosis, treatment, and a proposed agenda for research and development. Lancet Infect Dis 2:569–578Google Scholar
  37. 37.
    Price RN, Douglas NM, Anstey NM (2009) New developments in Plasmodium vivax malaria: severe disease and the rise of chloroquine resistance. Curr Opin Infect Dis 22:430–435PubMedGoogle Scholar
  38. 38.
    Campbell CC (1991) Challenges facing antimalarial therapy in Africa. J Infect Dis 163:1207–1211PubMedGoogle Scholar
  39. 39.
    Bjorkman A, Phillips-Howard PA (1990) The epidemiology of drug-resistant malaria. Trans R Soc Trop Med Hyg 84:177–180PubMedGoogle Scholar
  40. 40.
    Wongsrichanalai C, Pickard AL, Wernsdorfer W, Meshnick SR (2002) Epidemiology of drug-resistant malaria. Lancet Infect Dis 2:209–218PubMedGoogle Scholar
  41. 41.
    Aramburu Guarda J, Ramal Asayag C, Witzig R (1999) Malaria reemergence in the Peruvian Amazon Region. Emerg Infect Dis 5:209–215PubMedGoogle Scholar
  42. 42.
    Gosling RD, Cairns ME, Chico RM, Chandramohan D (2010) Intermittent preventive treatment against malaria: an update. Expert Rev Anti Infect Ther 8:589–606PubMedGoogle Scholar
  43. 43.
    Peters W (1987) Resistance of Human Malaria I, III, and IV. In: Chemotherapy and drug resistance in malaria, 2nd edn. Academic Press, London, pp 543–568, 593–658, 659–786Google Scholar
  44. 44.
    Zalis MG, Pang L, Silveria MS, Milhous WK, Wirth DF (1998) Characterization of Plasmodium falciparum isolated from the Amazon region of Brazil: evidence for quinine resistance. Am J Trop Med Hyg 58:630–637PubMedGoogle Scholar
  45. 45.
    Jelinek T, Grobusch MP, Loscher T (2001) Patterns of Plasmodium falciparum drug resistance in nonimmune travelers to Africa. Eur J Clin Microbiol Infect Dis 20:284–286PubMedGoogle Scholar
  46. 46.
    Shanks GD (1994) The rise and fall of mefloquine as an antimalarial drug in Southeast Asia. Mil Med 159:275–281PubMedGoogle Scholar
  47. 47.
    Wongsrichanalai C, Sirichaisinthop J, Karwacki JJ, Congpuong K, Miller RS, Pang L, Thimassarn K (2001) Drug resistant malaria on the Thai-Myanmar and Thai-Cambodian borders. Southeast Asian J Trop Med Public Health 32:41–49PubMedGoogle Scholar
  48. 48.
    Wernsdorfer WH (1994) Epidemiology of drug resistance in malaria. Acta Trop 56:143–156PubMedGoogle Scholar
  49. 49.
    Looareesuwan S, Viravan C, Webster HK, Kyle DE, Hutchinson DR, Canfield CJ (1996) Clinical studies of atovaquone, alone or in combination with other antimalarial drugs for treatment of acute uncomplicated malaria in Thailand. Am J Trop Med Hyg 54:62–66PubMedGoogle Scholar
  50. 50.
    Muehlen M, Schreiber J, Ehrhardt S, Otchwenah R, Jelinek J, Bienzle U, Mockenkaupt FP (2004) Short communication: prevalence of mutations associated with resistance to atovaquone and to the antifolate effect of proguanil in Plasmodium falciparum isolates in Northern Ghana. Trop Med Int Health 9:361–363PubMedGoogle Scholar
  51. 51.
    Happi CT, Ghotosho GO, Folarin OA et al (2006) Confirmation of emergence of mutations associated with atovaquone-proguanil resistance in unexposed Plasmodium falciparum isolates from Africa. Malar J 5:82PubMedGoogle Scholar
  52. 52.
    Thimasarn K, Sirichaisinthop J, Vijaykadya S et al (1995) In vivo study of the response of Plasmodium falciparum to standard mefloquine/sulfadoxine/pyrimethamine (MSP) treatment among gem miners returning to Cambodia. Southeast Asia J Trop Med Public Health 26:204–212Google Scholar
  53. 53.
    Alker AP, Lim P, Sem R et al (2007) Pfmdr1 and in vivo resistance to artesunate-mefloquine in falciparum malaria on the Cambodian-Thai border. Am J Trop Med Hyg 76:641–647PubMedGoogle Scholar
  54. 54.
    Wongsrichanalai C, Meshnick SR (2008) Declining artesunate-mefloquine efficacy against falciparum malaria on the Cambodia-Thailand border. Emerg Infect Dis 14:716–719PubMedGoogle Scholar
  55. 55.
    Greenwood B, Marsh K, Snow R (1991) Why do some African children develop severe malaria? Parasitol Today 7:277–281PubMedGoogle Scholar
  56. 56.
    Hastings IM, D’Alessandro U (2000) Modeling a predictable disaster: The rise and spread of drug-resistant malaria. Parasitol Today 16:340–347PubMedGoogle Scholar
  57. 57.
    Molyneux DH, Floyd K, Barnish G, Feure EM (1999) Transmission control and drug resistance in malaria: a crucial interaction. Parasitol Today 15:238–240PubMedGoogle Scholar
  58. 58.
    Draper CG, Brubaker G, Geser A, Kilimali VA, Wernsdorfer WH (1985) Serial studies on the evolution of drug resistance in an area of East Africa, receiving intermittent chemosuppression. Bull World Health Organ 63:109–118PubMedGoogle Scholar
  59. 59.
    Watkins WM, Mosobo M (1993) Treatment of Plasmodium falciparum malaria with pyrimethamine-sulfadoxine: selective pressure for resistance is a function of long elimination half-life. Trans R Soc Trop Med Hyg 192:130–134Google Scholar
  60. 60.
    Stepniewska K, White NJ (2008) Pharmacokinetic determinant of selection for antimicrobial drug resistance. Antimicrob Agents Chemother 52:1589–1596PubMedGoogle Scholar
  61. 61.
    Djimde AA, Fofana B, Sagara I et al (2008) Efficacy, safety and selection of molecular markers of drug resistance by two ACTs in Mali. Am J Trop Med Hyg 78:455–461PubMedGoogle Scholar
  62. 62.
    Martensson A, Stromberg J, Sisowath C et al (2005) Efficacy of artesunate plus amodiaquine versus that of artemether-lumefantrine for the treatment of uncomplicated childhood Plasmodium falciparum malaria in Zanzibar Tanzania. Clin Infect Dis 41:1079–1086PubMedGoogle Scholar
  63. 63.
    White NJ, Stepniewska K, Barnes K, Price RN, Simpson J (2008) Simplified antimalarial therapeutic monitoring: using the 7-day drug level? Trends Parasitol 24:159–163PubMedGoogle Scholar
  64. 64.
    Simpson JA, Watkins ER, Rn P, Aarons L, Kyle DE, White NJ (2000) Mefloquine pharmacokinetic-pharmacodynamic models: implications for dosing and resistance. Antimicrob Agents Chemother 44:3414–3424PubMedGoogle Scholar
  65. 65.
    Kofoed PE, Lopez F, Johansson P, Sandstrom A, Hedegaard K, Aaby P, Rombo L (2002) Treatment of children with Plasmodium falciparum malaria with chloroquine in Guinea-Bissau. Am J Trop Med Hyg 67:28–31PubMedGoogle Scholar
  66. 66.
    Ursing J, Schmidt BA, Lebbad M, Kofoed PE, Dias F, Gill JP, Rombo L (1990) Chloroquine resistant P. falciparum prevalence is low and unchanged between 1990 and 2003 in Guinea-Bissan effect of high chloroquine dosage? Infect Genet Evol 7:555–561Google Scholar
  67. 67.
    Walliker D, Quakyi IA, Wellems TE et al (1987) Genetic analysis of the human malaria parasite Plasmodium falciparum. Science 236:1661–1666PubMedGoogle Scholar
  68. 68.
    Su X, Ferdig MT, Huang Y et al (1999) A genetic map and recombination parameters of the human malaria parasite Plasmodium falciparum. Science 286:1351–1353PubMedGoogle Scholar
  69. 69.
    Rathod PK, McErlean T, Lee PC (1997) Variations in frequencies of drug resistance in Plasmodium falciparum. Proc Natl Acad Sci U S A 94:9389–9393PubMedGoogle Scholar
  70. 70.
    Travassos MA, Laufer MK (2009) Resistance to antimalarial drugs: molecular, pharmacological and clinical considerations. Pediatr Res 65:64–70Google Scholar
  71. 71.
    Daily JP (2006) Antimicrobial drug therapy: the role of parasite biology and drug resistance. J Clin Pharmacol 46:1487–1497PubMedGoogle Scholar
  72. 72.
    Olliaro PL (2001) Mode of action and mechanisms of resistance for antimalarial drugs. Pharmacol Ther 89:207–219PubMedGoogle Scholar
  73. 73.
    Koppe SHI, Vaughan AM, Boddey JA, Cowman AF (2010) That was then, but this is now: malaria research in the time of an eradication agenda. Science 328:862–866Google Scholar
  74. 74.
    Eckstein-Ludwig U, Webb RJ, Van Goethem ID et al (2003) Artemisinins target the SERCA of Plasmodium falciparum. Nature 424:957–961PubMedGoogle Scholar
  75. 75.
    Bunwag D, Harinasuta T, Pinichpongse S, Suntharasami P (1980) Effect of primaquine on gametocytes of Plasmodium falciparum in Thailand. Lancet 2:91Google Scholar
  76. 76.
    Buckling A, Ranford-Cartwright LC, Miles A, Read AF (1999) Chloroquine increases Plasmodium falciparum gametocytogenesis in vitro. Parasitology 8(pt. 4):339–346Google Scholar
  77. 77.
    Kumar N, Zheng H (1990) Stage-specific gametocystocidal effect in vitro of the antimalaria drug qinghaosu on Plasmodium falciparum. Parasitol Res 76:214–218PubMedGoogle Scholar
  78. 78.
    Targett C, Drakeley C, Jawara M et al (2001) Artesunate reduces but does not prevent post-treatment transmission of Plasmodium falciparum to Anopheles gambiae. J Infect Dis 183:1254–1259PubMedGoogle Scholar
  79. 79.
    Wellens TE, Walker-Jonath A, Panton LJ (1991) Genetic mapping of the chloroquine resistance locus on Plasmodium falciparum chromosome 7. Proc Natl Acad Sci U S A 88:3382–3386Google Scholar
  80. 80.
    Fidock DA, Nomura T, Talley AK et al (2000) Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. Mol Cell 6:861–871PubMedGoogle Scholar
  81. 81.
    Djimde A, Doumbo OK, Cortese JK et al (2001) A molecular marker for chloroquine-resistant falciparum malaria. N Engl J Med 344:257–263PubMedGoogle Scholar
  82. 82.
    Price RN, Uhlemann AC, Brockman A et al (2004) Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene-copy number. Lancet 364:438–447PubMedGoogle Scholar
  83. 83.
    Nzila AM, Mberu EK, Sulo J et al (2000) Towards an understanding of the mechanism of pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: genotyping of dihydrofolate reductase and dihydropteroate synthase of Kenyan parasites. Antimicrob Agents Chemother 44:991–996PubMedGoogle Scholar
  84. 84.
    Jambou R, Legrand E, Niang M et al (2005) Resistance of Plasmodium falciparum field isolates to in vitro artemether and point mutations of the SERCA-type PfATPase6. Lancet 366:1960–1963PubMedGoogle Scholar
  85. 85.
    Sharma VP (2006) Vector genetics in malaria control. In: Dronamraju KR, Arese P (eds) Malaria: genetic and evolutionary aspects. Springer, New York, pp 147–167Google Scholar
  86. 86.
    Miller LH, Peirce SK (2009) Perspective on malaria eradication: Is eradication possible without modifying the mosquito? J Infect Dis 200:1644–1645PubMedGoogle Scholar
  87. 87.
    Packard RA, Gadelha P (1994) A land filled with mosquitoes: Fred L. Soper, The Rockefeller Foundation, and the Anopheles gambiae invasion of Brazil. Parrasitologia 36:197–213Google Scholar
  88. 88.
    Afrane YA, Little TJ, Lawson BW, Githeko AK, Yan G (2008) Deforestation and vectorial capacity of Anopheles gambiae Giles mosquitoes in malaria transmission Kenya. Emerg Infect Dis 14:1533–1538PubMedGoogle Scholar
  89. 89.
    Githeco A, Clive S (2005) The history of malaria control in Africa: lessons learned and future perspectives. In: Ebi K, Smith J, Burton I (eds) Integration of public health with adaptation to climate change: lessons learned and new directions. Francis & Taylor, LondonGoogle Scholar
  90. 90.
    Munyekenye GO, Githeko AK, Zhou G, Mushinzimana E, Minakawa N, Yan G (2005) Plasmodium falciparum spatial analysis in Western Kenya highlands. Emerg Infect Dis 10:1571–1577Google Scholar
  91. 91.
    Cohuet A, Harris C, Robert V, Fontenille D (2009) Evolutionary forces on anopheles: what makes a malaria vector? Trends Parasitol 26:130–136Google Scholar
  92. 92.
    MacDonald G (1957) The epidemiology and control of malaria. Oxford University Press, OxfordGoogle Scholar
  93. 93.
    Noden BH, Kent MD, Beier JC (1995) The impact of variations in temperature on early Plasmodium falciparum development in Anopheles stephensi. Parasitology 111:539–545PubMedGoogle Scholar
  94. 94.
    Lacroix R, Mukabana WR, Gouagna LC, Koella JC (2005) Malaria infection increases attractiveness of humans to mosquitoes. PLoS Biol 3:e298PubMedGoogle Scholar
  95. 95.
    Koella JC, Sørensen FL, Anderson RA (1998) The malaria parasite, Plasmodium falciparum increases the frequency of multiple feeding of its mosquito vector, Anopheles gambiae. Proc Biol Sci 265:763–768PubMedGoogle Scholar
  96. 96.
    Ansell J, Hamilton KA, Pinder M, Walraven GEL, Lindsay SW (2002) Short-range attractiveness of pregnant women to Anopheles gambiae mosquitoes. Trans R Soc Trop Med Hyg 96:113–116PubMedGoogle Scholar
  97. 97.
    Baleta A (2009) Insecticide resistance threatens malaria control in Africa (news). Lancet 374:1581–1582PubMedGoogle Scholar
  98. 98.
    Fusein G, Ebsworth P, Jones S, Knight D (2011) The efficacy of ACTELLIC 50E, primiphos methyl for indoor residual spraying in Ahafo, Ghana: an area of high vector resistance to pyrethroids and organochlorines. J Med Entomol 48:437–440Google Scholar
  99. 99.
    Yewhalaw D, Bartel WV, Denis L, Cooseman M, Duchateau L, Speybroeck N (2010) First evidence of high knockdown resistance frequency in Anopheles arabiensis (Diptera; Cullicidae) from Ethiopia. Am J Trop Med Hyg 83:122–125PubMedGoogle Scholar
  100. 100.
    Awolola TS, Oduola OA, Strode C, Koekemoer LL, Brook B, Ranson H (2009) Evidence of multiple pyrethroid resistance mechanisms in the malaria vector Anopheles gambiae sensustricto from Nigeria. Trans R Soc Trop Med Hyg 103:1139–1145PubMedGoogle Scholar
  101. 101.
    Trape JF, Tall A, Diagne N et al (2011) Malaria morbidity and pyrethroid resistance after the introduction of insecticide-treated bednets and artemisinin-based combination therapies: a longitudinal study. Lancet Infect Dis 11(12):925–932, PMID;21856232PubMedGoogle Scholar
  102. 102.
    Baleta A (2009) Insecticide resistance threatens malaria control in Africa (Word Report). Lancet 374:1581–1582PubMedGoogle Scholar
  103. 103.
    Ranson H, N’Guessan R, Lines J, Moirouxa W, Nkuni Z, Corbel V (2011) Pyrethroid resistance in African anopheline mosquitoes: what are the implications for malaria control? Trends Parasitol 29:91–98Google Scholar
  104. 104.
    Donnelly MJ, Corbel V, Weetman D, Wilding CS, Williamson MS, Blair WC 4th (2009) Does Kdr genotype predict insecticide resistance phenotype in mosquitoes? Trends Parasitol 25:213–219PubMedGoogle Scholar
  105. 105.
    Hemingway J, Beaty BJ, Rowland M, Scott TW, Sharp BC (2006) The innovative vector control consortium: improved control of mosquito-borne diseases. Trends Parasitol 22:308–312PubMedGoogle Scholar
  106. 106.
    Raghavendra K, Barik TH, Sharma P, Bhatt RM, Srivastava HC, Srechhari U, Dash AP (2011) Chlorfenapyr: a new insecticide with novel mode of action can control pyrethroid resistant malaria vectors. Malar J 10:16PubMedGoogle Scholar
  107. 107.
    N’Guessan R, Boko P, Odjo A, Chabi J, Akogbeto M, Rowland M (2010) Control of pyrethroid and DDT resistant Anopheles gambiae by application of indoor residual spraying or mosquito nets treated with long-lasting organophosphate insecticide, chlorpyrifos-methyl. Malar J 9:44PubMedGoogle Scholar
  108. 108.
    Mosqueira B, Chabi J, Chandre F, Akogbeto M, Hougard JM, Carnevale P, Mas-Coma S (2010) Efficacy of an insecticide paint against malaria vectors and nuisance in West Africa – Part 2: field evaluation. Malar J 9:340–341PubMedGoogle Scholar
  109. 109.
    Pennetier C, Costantini C, Corbel V et al (2008) Mixture for controlling insecticide-resistant malaria vectors. Emerg Infect Dis 14:1707–1714PubMedGoogle Scholar
  110. 110.
    Kawaguchi I, Sasaki A, Mogi M (2004) Combining zooprophylaxis and insecticide spraying: a malaria control strategy limiting the development of insecticide resistance in vector mosquitoes. Proc R Soc Lond Ser B Biol Sci 271:301–309Google Scholar
  111. 111.
    Farenhorst M, Mouatcho JC, Kikonkie CK et al (2009) Fungal infection counters insecticide resistance in African malaria mosquitoes. Proc Natl Acad Sci U S A 106:17443–17447PubMedGoogle Scholar
  112. 112.
    Corby-Harris V, Drexler A, Watkins de Jong L et al (2010) Activation of Akt signaling reduces the prevalence and intensity of malaria parasite infection and lifespan in Anopheles stephensi mosquitoes. PLoS Pathog 6:e1001003PubMedGoogle Scholar
  113. 113.
    Wise de Valdez MR, Nimmo D, Betz J, Gong HF, James AA, Alphey L, Black WC IV (2011) Genetic elimination of dengue vector mosquitoes. Proc Natl Acad Sci U S A 108:4772–4775PubMedGoogle Scholar
  114. 114.
    Subbaraman N (2011) Science snipes at Oxitec Transgenic mosquito trial (News). Nat Biotechnol 29:9–11PubMedGoogle Scholar
  115. 115.
    Ostera GR, Gostin LO (2011) Biosafety concerns involving genetically modified mosquitoes to combat dengue in developing countries. JAMA 305:930–931PubMedGoogle Scholar
  116. 116.
    Hoffmann AA, Montgomery BL, Popovici J et al (2011) Successful establishment of Wolbachia in Aedes population to suppress dengue transmission. Nature 476:454–457PubMedGoogle Scholar
  117. 117.
    Douglas AD, Andrews L, Drapner SJ et al (2011) Substantially reduced prepatent parasite multiplication rates are associated with naturally acquired immunity to Plasmodium falciparum. J Infect Dis 203:1337–1340PubMedGoogle Scholar
  118. 118.
    Langhorne J, Ndungu FM, Sponaas AM, Marsh K (2008) Immunity to malaria: more questions than answers. Nat Immunol 9:725–732PubMedGoogle Scholar
  119. 119.
    Hoffman SL, Billingsley PF, James E et al (2010) Development of a metabolically active non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria. Hum Vaccin 6:97–106PubMedGoogle Scholar
  120. 120.
    Aponte JJ, Aide P, Renom M et al (2007) Safety of the RTS1S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomized controlled phase I/IIb trial. Lancet 370:1543–1551PubMedGoogle Scholar
  121. 121.
    Sacarlal J, Aide P, Aponte JJ et al (2009) Long-term safety and efficacy of the RTS1S/AS02A malaria vaccine in Mozambican children. J Infect Dis 200:329–336PubMedGoogle Scholar
  122. 122.
    Bejon P, Cook J, Bergmann-Leitner E et al (2011) Effect of the pre-erythrocytic candidate malaria vaccine RTS1S/AS01E on blood stage immunity in young children. J Infect Dis 204:9–18PubMedGoogle Scholar
  123. 123.
    Agnandji ST, Lell B, Soulanoudjingar SS et al (2011) The RTS1S clinical trials partnership. First results of phase 3 trial of RTS1S/AS01 malaria vaccine in African children. N Engl J Med 365:1163–1175Google Scholar
  124. 124.
    Wu Y, Ellis RD, Shaffer D et al (2008) Phase I trial of malaria transmission blocking vaccine candidates Pfs25 and Pvus25 formulated with montanide ISA51. PLoS One 3:e2636PubMedGoogle Scholar
  125. 125.
    Vogel G (2010) The ‘Do Unto Others’ malaria vaccine (news). Science 328:847–848PubMedGoogle Scholar
  126. 126.
    Thera MA, Doumbo OK et al (2011) A field trial to assess a blood-stage malaria vaccine. N Engl J Med 365:1004–1131PubMedGoogle Scholar
  127. 127.
    World Health Organization (WHO) (2010) Malaria rapid diagnostic test performance. Results of a WHO product testing of malaria RDTs: round 2. WHO 2009, Geneva, Switzerland. Available at: http//­diagnostic-test-report-round2.html
  128. 128.
    Hendriksen ICE, Mtove G, Pedro AJ et al (2011) Evaluation of a PfHRP2 and a pLDH-based rapid diagnostic test for the diagnosis of severe malaria in 2 populations of African children. J Infect Dis 52:1100–1107Google Scholar
  129. 129.
    Nebehay S (2011) Drug-resistant malaria could spread fast: expert warns. Malaria. Reuters Health. 12 Jan 2011.
  130. 130.
    Choi SR, Mukherjee P, Avery MA (2008) The fight against resistant malaria: novel plasmodial targets and antimicrobial drugs. Curr Med Chem 15:161–171PubMedGoogle Scholar
  131. 131.
    Valechia N, Looareesuwan S, Mortensson A et al (2010) Artenolane, a new synthetic trioxolane for treatment of uncomplicated Plasmodium falciparum malaria: a phase II multicenter, randomized, dose-finding clinical trial. Clin Infect Dis 51:684–691Google Scholar
  132. 132.
    Henry M, Alibert S, Orlandi-Pradines E et al (2006) Chloroquine resistance reversal agents as promising antimicrobial drugs. Curr Drug Targets 7:935–948PubMedGoogle Scholar
  133. 133.
    Egan TJ, Kaschula CH (2007) Strategies to reverse drug resistance in malaria. Curr Opin Infect Dis 20:598–604PubMedGoogle Scholar
  134. 134.
    Laufer MK, Thesting PC, Eddington ND et al (2006) Return of chloroquine antimalarial efficacy in Malawi. N Engl J Med 355:1959–1966PubMedGoogle Scholar
  135. 135.
    Hand CC, Meshnick SR (2011) Is chloroquine making a comeback? J Infect Dis 203:11–12PubMedGoogle Scholar
  136. 136.
    Ursing J, Kofoed PE, Rodriques A, Blessborn D, Thoft-Nielsen R, Bjorkman A, Rombo L (2011) Similar efficacy and tolerability of double-dose chloroquine and artemether-lumefantrine for treatment of Plasmodium falciparum in Guinea-Bissau.: a randomized trial. J Infect Dis 203:109–116PubMedGoogle Scholar
  137. 137.
    Olliaro P, Wells TN (2009) The global portfolio of new antimalarial medicines under development. Clin Pharmacol Ther 85:584–595PubMedGoogle Scholar
  138. 138.
    White NJ, Olliaro PL (1996) Strategies for the prevention of antimalarial drug resistance: rationale for combination chemotherapy for malaria. Parasitol Today 12:399–401PubMedGoogle Scholar
  139. 139.
    Maude RJ, Pontavornpinyo W, Savalamba S et al (2009) The last man standing is the most resistant: eliminating artemisinin-resistant malaria in Cambodia. Malar J 8:31PubMedGoogle Scholar
  140. 140.
    Dondorp AM, Fairhurst RC, Slutsker L et al (2011) The threat of artemisinin-resistant malaria (perspective). N Engl J Med 365:1073–1075PubMedGoogle Scholar
  141. 141.
    Saralamba S, Pan-Ngum W, Maude RJ et al (2011) Intrahost modeling of artemisinin resistance in Plasmodium falciparum. Proc Natl Acad Sci U S A 108:397–402PubMedGoogle Scholar
  142. 142.
    WHO (2011) Global plan for artemisinin resistance containment. World Health Organization, Geneva.
  143. 143.
    Tatem AJ, Smith DL, Gething PW, Kabaria CW, Snow RW, Hay SI (2010) Ranking of elimination feasibility between malaria-endemic countries. Malaria elimination 2. Lancet 376:1579–1591PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Department of MedicineUniversity of TorontoTorontoCanada
  2. 2.Division of Infectious DiseasesSt. Michael’s HospitalTorontoCanada

Personalised recommendations